Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)1.59bn
- Net income in SEK223.25m
- Incorporated2004
- Employees228.00
- LocationCamurus ABIdeongatan 1ALUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioGaia AB | 1.37bn | 401.72m | 11.21bn | 220.00 | 28.91 | 7.37 | 26.31 | 8.18 | 3.98 | 3.98 | 13.56 | 15.60 | 0.6749 | -- | -- | 6,520,886.00 | 19.80 | 15.47 | 22.19 | 16.93 | 73.84 | 73.30 | 29.34 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
Calliditas Therapeutics AB | 1.60bn | -480.36m | 12.36bn | 222.00 | -- | 104.29 | -- | 7.72 | -8.95 | -8.95 | 29.83 | 1.98 | 0.9267 | 3.62 | 8.68 | 8,212,380.00 | -27.80 | -26.46 | -35.11 | -30.27 | 93.46 | -- | -30.00 | -76.59 | 2.59 | -3.07 | 0.9042 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
Bonesupport Holding AB | 735.16m | 288.78m | 21.53bn | 127.00 | 74.75 | 34.67 | 71.91 | 29.28 | 4.38 | 4.38 | 11.13 | 9.44 | 1.30 | 0.6001 | 4.88 | 7,001,534.00 | 51.17 | -9.08 | 62.05 | -11.28 | 92.22 | 90.25 | 39.28 | -11.65 | 3.07 | -- | 0.0239 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Vimian Group AB | 3.91bn | 111.36m | 22.28bn | 1.10k | 187.63 | 2.93 | 44.86 | 5.70 | 0.2297 | 0.2297 | 8.18 | 14.69 | 0.3429 | 2.77 | 6.26 | 3,554,878.00 | 1.04 | -- | 1.15 | -- | 47.18 | -- | 3.05 | -- | 1.33 | 2.73 | 0.2119 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
Bavarian Nordic A/S | 9.25bn | 1.08bn | 29.13bn | 1.38k | 26.83 | 1.82 | 14.69 | 3.15 | 9.06 | 9.06 | 78.44 | 133.68 | 0.4157 | 1.50 | 5.10 | 4,410,899.00 | 4.83 | 1.21 | 6.24 | 1.48 | 56.91 | 53.72 | 11.63 | 4.06 | 0.9311 | -- | 0.0118 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
Camurus AB | 1.59bn | 223.25m | 38.88bn | 228.00 | 174.80 | 13.28 | 163.31 | 24.40 | 3.79 | 3.79 | 27.51 | 49.94 | 0.6122 | 1.09 | 4.86 | 7,480,770.00 | 8.58 | -1.13 | 10.10 | -1.41 | 92.01 | 90.05 | 14.01 | -1.63 | 7.11 | -- | 0.0071 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
ALK-Abello A/S | 7.88bn | 1.05bn | 54.82bn | 2.81k | 57.56 | 8.01 | 36.27 | 6.96 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Orion Oyj | 14.28bn | 2.64bn | 74.92bn | 3.82k | 28.32 | 8.65 | 23.59 | 5.25 | 1.66 | 1.66 | 8.98 | 5.42 | 0.9106 | 1.50 | 6.41 | 346,641.00 | 16.79 | 19.47 | 21.27 | 24.16 | 56.23 | 59.38 | 18.44 | 20.71 | 1.29 | 77.55 | 0.2571 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
Swedish Orphan Biovitrum AB (publ) | 23.71bn | 2.14bn | 116.23bn | 1.77k | 53.49 | 3.09 | 19.92 | 4.90 | 6.13 | 6.13 | 69.42 | 106.08 | 0.3184 | 1.35 | 5.14 | 13,379,800.00 | 2.88 | 5.93 | 3.74 | 7.60 | 77.70 | 77.42 | 9.04 | 16.61 | 0.4918 | 3.07 | 0.3199 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 May 2024 | 2.61m | 4.45% |
Swedbank Robur Fonder ABas of 30 Aug 2024 | 1.97m | 3.36% |
Handelsbanken Fonder ABas of 31 Aug 2024 | 1.43m | 2.44% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 1.15m | 1.96% |
SEB Investment Management ABas of 30 Aug 2024 | 625.22k | 1.07% |
Lancelot Asset Management ABas of 31 Dec 2022 | 625.00k | 1.07% |
AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 May 2024 | 614.29k | 1.05% |
Devon Equity Management Ltd.as of 31 Aug 2024 | 589.48k | 1.01% |
Baillie Gifford & Co.as of 31 Aug 2024 | 521.05k | 0.89% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 454.64k | 0.78% |